Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today

Lexicon Pharmaceuticals stock surged nearly 6% after analyst Steve Seedhouse from Cantor Fitzgerald initiated coverage with an 'overweight' rating and $8 price target (over 4x the current $1.90 price). Seedhouse highlighted the company's progress on sotagliflozin, an FDA-approved heart failure drug being developed for hypertrophic cardiomyopathy, which works through a different mechanism than competing treatments.